See the paper online here: https://www.pnas.org/content/early/2020/02/07/1921649117 … [Read More...]
Congrats! This paper was an intense amount of work. We identified an exciting new design principle for targeted therapy and rational drug design. Preprint is here. Final manuscript is forthcoming! … [Read More...]
Our manuscript showing that CX-5461 acts through Topoisomerase II and creates collateral resistance to canonical Topoisomerase II poisons was just accepted at PNAS. This was a Terrific collaboration with Peter Bruno (Elledge Lab @ Harvard Med) and Michael Hemann (Koch … [Read More...]
WE ARE…THE PRITCHARD LAB
Justin Pritchard received his B.S. from U.C.L.A, and his Ph.D. from the labs of Mike Hemann(Cancer Genetics) and Doug Lauffenburger(Biological Engineering). Justin did a postdoc in pathogen genomics in Eric Rubin’s lab at Harvard University where he collaborated heavily with Matthew Waldor’s lab.
Haider studies approaches that combine drugs to target resistance during therapy. He graduated from the University of Virginia in 2016, where he studied Biomedical Engineering.
Scott is developing innovative ways to combine targeted cancer therapy with gene therapy. He does so by designing genetic constructs that offer control over a tumor’s evolution. Scott uses deterministic and stochastic dynamic modeling to predict the behavior of interacting cell populations and verifies these models in vitro.
Chuan is a medical doctor from Shanghai, China. Chuan’s specialty is oncology. He is interested in combination therapy in Ph+ ALL. Chuan started doing biological research in Professor Hai Jiang’s lab at the Shanghai Institute of Biochemistry and Cell Biology.
Bo graduated from MIT in 2015. As a visiting scientist, Bo uses data mining to understand the mechanisms of immune evasion and resistance to immunotherapy. In his free time he enjoys salsa dancing and traveling.
Lucia graduated from the University of California, Irvine in 2016 with a M.S. in Pharmacological Sciences. With few years of studying in cancer treatment ranging from chemo drug combinations to genetically engineered cells, Lucia have found her interest in cancer biology, particularly about how to overcome the problem of drug resistance. In Lucia’s free time, she enjoys crafting science-inspired decorations.